| Date | Title | Description |
| 02.05.2024 | Invitation to presentation of Orexo´s Q1 2024 Interim Report | Invitation to presentation of Orexo´s Q1 2024 Interim Report
Thu, May 02, 2024 09:00 CET Report this content
Uppsala, Sweden – May 2, 2024 – As previously communicated Orexo will announce the Interim Report for the first quarter of 2024 on ... |
| 26.04.2024 | Report from Orexo AB’s annual general meeting, 26 April 2024 | Report from Orexo AB’s annual general meeting, 26 April 2024
Fri, Apr 26, 2024 17:30 CET Report this content
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordan... |
| 17.04.2024 | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Wed, Apr 17, 2024 08:00 CET Report this content
Uppsala, Sweden – April 17, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the U... |
| 02.04.2024 | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
Tue, Apr 02, 2024 13:15 CET Report this content
Uppsala, Sweden – April 2, 2024. On March 13, 2024, Orexo AB (publ), (“Orexo” or the “Company”)... |
| 28.03.2024 | Orexo publishes the Annual and Sustainability Report for 2023 | Orexo publishes the Annual and Sustainability Report for 2023
Thu, Mar 28, 2024 08:00 CET Report this content
Uppsala, Sweden - March 28, 2024 – Orexo’s Annual and Sustainability Report for 2023 has been published and can be downloaded at, ... |
| 15.03.2024 | Correction: Notice of Annual General Meeting of Orexo | Correction: Notice of Annual General Meeting of Orexo
Fri, Mar 15, 2024 18:30 CET Report this content
The correction concerns the proposal regarding the number of board members as stated in the Swedish language version of the notice, which ... |
| 15.03.2024 | Notice of Annual General Meeting of Orexo | Notice of Annual General Meeting of Orexo
Fri, Mar 15, 2024 10:00 CET Report this content
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday... |
| 13.03.2024 | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
Wed, Mar 13, 2024 20:30 CET Report this content
Uppsala, Sweden – March 13, 2024. Ore... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 08.03.2024 | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
Fri, Mar 08, 2024 08:10 CET Report this content
Uppsala, Sweden – March 8, 2024 - Orexo AB (pu... |
| 08.03.2024 | Leading with purpose: Why Cecilia Coupland became an Orexo executive | Leading with purpose: Why Cecilia Coupland became an Orexo executive
Fri, Mar 08, 2024 14:30 CET Report this content
News Release – Uppsala, Sweden, Mars 8, 2024
In this interview to mark International Women’s Day 2024, Cecilia Coupland, SV... |
| 08.03.2024 | Orexo strengthens its sustainability work by establishing a social financing framework | Orexo strengthens its sustainability work by establishing a social financing framework
Fri, Mar 08, 2024 08:00 CET Report this content
Uppsala, Sweden, March 8, 2024 - Orexo AB (publ), (“Orexo” or the “Company”) (STO:ORX) (OTCQX:ORXOY) toda... |
| 12.02.2024 | Orexo and Sobi agree to advance feasibility study with AmorphOX | Orexo and Sobi agree to advance feasibility study with AmorphOX
Mon, Feb 12, 2024 08:00 CET Report this content Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery... |
| 06.02.2024 | Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC | Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
Tue, Feb 06, 2024 08:00 CET Report this content OX640 is Orexo’s nasal epinephrine powder product for the acute treatment of severe allergi... |
| 28.11.2023 | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
Tue, Nov 28, 2023 08:00 CET Report this content
OX124 is based on Orexo´s world-class drug delivery platform, amorphO... |
| 27.10.2023 | Orexo announces changes in the company´s Board of Directors | Orexo announces changes in the company´s Board of Directors
Fri, Oct 27, 2023 08:00 CET Report this content
Uppsala, Sweden – October 27, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces that Robin Evers, Senior Vice President, H... |
| 26.10.2023 | Report from Orexo´s extraordinary general meeting | Report from Orexo´s extraordinary general meeting
Thu, Oct 26, 2023 16:05 CET Report this content
Stockholm, Sweden, October 26, 2023
Election of new member of the board of directors
The extraordinary general meeting in Orexo AB (publ) on 2... |
| 26.10.2023 | Orexo´s Nomination Committee for the Annual General Meeting 2024 | Orexo´s Nomination Committee for the Annual General Meeting 2024
Thu, Oct 26, 2023 17:00 CET Report this content
Uppsala, Sweden – October 26, 2023 – Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26, a Nom... |
| 11.10.2023 | Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids | Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids
Wed, Oct 11, 2023 08:00 CET Report this content The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The s... |
| 18.09.2023 | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Mon, Sep 18, 2023 08:00 CET Report this content OX124 is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to... |
| 05.09.2023 | Orexo to participate in Pareto Securities´ 14[th] Annual Healthcare Conference 2023 | Orexo to participate in Pareto Securities´ 14[th] Annual Healthcare Conference 2023
Tue, Sep 05, 2023 14:00 CET Report this content
Uppsala, Sweden – September 5, 2023 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company... |
| 29.08.2023 | Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product | Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product
Tue, Aug 29, 2023 08:00 CET Report this content
Uppsala, Sweden – August 29, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the U... |
| 24.07.2023 | Orexo’s patent win for ZUBSOLV[®] appealed | Orexo’s patent win for ZUBSOLV[®] appealed
Mon, Jul 24, 2023 08:00 CET Report this content
Uppsala, Sweden – July 24, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma G... |
| 01.07.2023 | Orexo wins patent litigation for ZUBSOLV® in the US | Orexo wins patent litigation for ZUBSOLV® in the US
Sat, Jul 01, 2023 11:20 CET Report this content The court found Orexo´s patents valid and infringed by Sun The outcome once again confirms the strength of the company´s intellectual proper... |
| 19.06.2023 | OX640: Shaping the future of nasal powder epinephrine using the innovative amorphOX platform | OX640: Shaping the future of nasal powder epinephrine using the innovative amorphOX platform
Mon, Jun 19, 2023 10:00 CET Report this content
Orexo is breaking new ground in the area of anaphylaxis with OX640, an innovative nasal powder epin... |
| 18.04.2023 | Report from Orexo AB’s annual general meeting | Report from Orexo AB’s annual general meeting
Tue, Apr 18, 2023 19:30 CET Report this content
Uppsala, April 18, 2023
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 18 April 2023 resolved, in... |
| 03.04.2023 | Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 | Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Mon, Apr 03, 2023 08:00 CET Report this content
Uppsala, Sweden – April 3, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expect... |
| 28.03.2023 | Orexo publishes the Annual and Sustainability Report for 2022 | Orexo publishes the Annual and Sustainability Report for 2022
Tue, Mar 28, 2023 14:45 CET Report this content
Uppsala, Sweden - March 28, 2023 – Orexo’s Annual and Sustainability Report for 2022 has been published and can be downloaded at, ... |
| 28.03.2023 | How the drug industry uses fear of fentanyl to extract more profit from naloxone | As the U.S. drug crisis has accelerated, the pharmaceutical industry has jumped into action — particularly when it comes to naloxone, the drug used to reverse opioid overdoses.
In recent years, companies have introduced a dizzying array of ... |
| 15.03.2023 | Notice of Annual General Meeting of Orexo | Notice of Annual General Meeting of Orexo
Wed, Mar 15, 2023 13:00 CET Report this content
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesda... |
| 15.03.2023 | Orexo postpones publication of the Annual Report | Orexo postpones publication of the Annual Report
Wed, Mar 15, 2023 18:00 CET Report this content
Uppsala, Sweden – March 15, 2023 – Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for ... |
| 03.02.2023 | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Fri, Feb 03, 2023 08:00 CET Report this content OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as ... |
| 03.02.2023 | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioids If approved, the US launch is expected to be initiated in H1 2024
U... |
| 09.01.2023 | Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies | Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
Mon, Jan 09, 2023 08:00 CET Report this content Orexo has successfully formulated Covid-19 spike protein in the propriet... |
| 09.12.2022 | Digital Therapeutics: the future of healthcare is happening now | Digital Therapeutics: the future of healthcare is happening now
Fri, Dec 09, 2022 10:00 CET Report this content
In this interview, Megan Coder, Founder of the Digital Therapeutics Alliance[i] (DTA) and Chief Policy Officer, shares her insig... |
| 28.10.2022 | Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD | Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Fri, Oct 28, 2022 08:00 CET Report this content Study evaluating effica... |
| 07.09.2022 | Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients | Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
Wed, Sep 07, 2022 16:30 CET Report this content
Uppsala, Sweden – September 7, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today anno... |
| 01.09.2022 | First patent issued in Europe for Orexo’s adrenaline product OX640 | First patent issued in Europe for Orexo’s adrenaline product OX640
Thu, Sep 01, 2022 08:00 CET Report this content
Uppsala, Sweden – September 1, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the European Patent Offi... |
| 31.08.2022 | Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference | Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Wed, Aug 31, 2022 10:00 CET Report this content
Uppsala, Sweden – August 31, 2022 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceutic... |
| 13.07.2022 | Orexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule | Orexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule
Wed, Jul 13, 2022 08:00 CET Report this content Orexo is granted a Veterans Affairs Federal Supply Schedule contract for deprexis® in the US ... |
| 05.07.2022 | Orexo’s nasal adrenaline rescue medication OX640 enters clinical development | Orexo’s nasal adrenaline rescue medication OX640 enters clinical development
Tue, Jul 05, 2022 08:00 CET Report this content OX640 has the potential to provide important benefits to patients and healthcare systems ensuring the correct adren... |
| 07.06.2022 | Dr. Joseph R. Volpicelli, head of the Volpicelli Addiction Treatment Center, on VatorNews podcast | The Volpicelli Addiction Treatment Center uses psychosocial methods and digital therapeutics.
Vator · Interview with Joseph R. Volpicelli, head of the Volpicelli Addiction Treatment Center
Bambi Francisco Roizen speaks with Dr. Joseph R. Vo... |
| 27.04.2022 | Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis | Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis
Wed, Apr 27, 2022 08:00 CET Report this content
Uppsala, Sweden – April 27, 2022 – Orexo AB (publ.), (STO:... |
| 21.04.2022 | Report from Orexo AB’s annual general meeting | Report from Orexo AB’s annual general meeting
Thu, Apr 21, 2022 18:00 CET Report this content
Uppsala, Sweden - April 21, 2022
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 21 April 2022 res... |
| 31.03.2022 | Orexo publishes 2021 Annual Report | Orexo publishes 2021 Annual Report
Thu, Mar 31, 2022 08:00 CET Report this content
Uppsala, Sweden - March 31, 2022 – Orexo’s Annual Report for the 2021 has been published. The Annual Report can be downloaded on the company’s website, www.o... |
| 21.03.2022 | Notice of Annual General Meeting of Orexo | Notice of Annual General Meeting of Orexo
Mon, Mar 21, 2022 16:45 CET Report this content
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Thursd... |
| 11.03.2022 | Orexo appoints Fredrik Järrsten as new CFO | Orexo appoints Fredrik Järrsten as new CFO
Fri, Mar 11, 2022 08:00 CET Report this content
Uppsala, Sweden – March 11, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new ... |
| 24.02.2022 | Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List | Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List
Thu, Feb 24, 2022 08:00 CET Report this content
ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 ZUBSOLV... |
| 22.12.2021 | Robert Rönn, SVP and Head of R&D: “My vision is to develop several new drugs based on amorphOX™” | Robert Rönn, SVP and Head of R&D: “My vision is to develop several new drugs based on amorphOX™” Wed, Dec 22, 2021 10:30 CET
In recent years, Orexo has invested in its development pipeline with a focus on OX124, a life-saving overdose m... |
| 02.12.2021 | Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform | UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic r... |
| 02.12.2021 | Orexo develops a nasal adrenaline medication based on the novel amorphOX platform | The development pipeline is broadening with a nasal adrenaline medication, targeting a global and growing unmet medical need If approved, the medication would provide important benefits to patients and health care systems ensuring the corre... |
| 02.12.2021 | Orexo develops a nasal adrenaline medication based on the novel amorphOX[TM] platform | Orexo develops a nasal adrenaline medication based on the novel amorphOX[TM] platform Thu, Dec 02, 2021 08:00 CET
The development pipeline is broadening with a nasal adrenaline medication, targeting a global and growing unmet medical need I... |
| 26.11.2021 | Orexo provides information about its new proprietary drug delivery platform – amorphOX[TM] | Orexo provides information about its new proprietary drug delivery platform – amorphOX[TM] Fri, Nov 26, 2021 08:00 CET
amorphOXTM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products wit... |
| 16.11.2021 | Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 | Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 Tue, Nov 16, 2021 08:00 CET
The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailabili... |
| 16.11.2021 | Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 | The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosin... |
| 01.11.2021 | Orexo´s Nomination Committee for the Annual General Meeting 2022 | Orexo´s Nomination Committee for the Annual General Meeting 2022 Mon, Nov 01, 2021 08:00 CET
Uppsala, Sweden – November 1, 2021 – Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents... |
| 18.10.2021 | MODIA™ paper published in the Journal of Medical Internet Research Mental Health | MODIA™ paper published in the Journal of Medical Internet Research Mental Health Mon, Oct 18, 2021 08:00 CET
Uppsala, Sweden – October 18, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announced the publication of a manuscript, “A ... |
| 16.07.2021 | Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial | Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial Fri, Jul 16, 2021 08:00 CET The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the second half of 2022. OX124 is des... |
| 12.07.2021 | Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® | Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® Mon, Jul 12, 2021 08:00 CET With more than 300,000 users Sober Grid is the largest gl... |
| 12.07.2021 | Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo | Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo Mon, Jul 12, 2021 14:00 CET
The digital therapeutics, which help manage problematic alcohol use and depression through a... |
| 14.06.2021 | OREXO AB (PUBL)
Orexo : Partner Gesynta Pharma announces progresses in phase II study of OX-MPI and submits IND with FDA | Uppsala, Sweden - Juni 14, 2021 - Orexo's partner, Gesynta Pharma, today announces that more than half of the patients in the ongoing phase II study of the drug candidate OX-MPI (GS-248) have been recruited. Gesynta Pharma, who owns all the... |
| 02.06.2021 | OREXO AB (PUBL)
Orexo : continues to strengthen ZUBSOLV's patent portfolio with two new patents | Uppsala, Sweden - June 2, 2021 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents relating to ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone ta... |
| 02.06.2021 | Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents | Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents Wed, Jun 02, 2021 08:00 CET
Uppsala, Sweden – June 2, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (US... |
| 02.06.2021 | OREXO AB (PUBL)
Orexo : continues to strengthen ZUBSOLV´s patent portfolio with two new patents | UPPSALA, Sweden, June 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents relating to ZUBSOLV®, Orexo's sublingual buprenorphine an... |
| 29.04.2021 | Orexo Q1 2021 Interim Report | UPPSALA, Sweden, April 29, 2021 /PRNewswire/ --
Q1 2021 summary
Total net revenues of SEK 132.3 m (175.0)
Net earnings of SEK -31.5 m (82.6)
EBITDA of SEK -23.9 m (39.1)
US Pharma segment (ZUBSOLV® US) net revenues of SEK 126.8 m (163.9), E... |
| 29.04.2021 | Orexo Q1 2021 Interim Report | Investing in future growth drivers
UPPSALA, Sweden, April 29, 2021 /PRNewswire/ --
Q1 2021 summary
Total net revenues of SEK 132.3 m (175.0)
Net earnings of SEK -31.5 m (82.6)
EBITDA of SEK -23.9 m (39.1)
US Pharma segment (ZUBSOLV® US) net... |
| 09.09.2020 | Orexo : and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | MORRISTOWN, N.J., Sept. 9, 2020 /PRNewswire/ -- Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic... |
| - | Orexo appeal Zubsolv® US district court decision | Uppsala, Sweden, December 8, 2016 – Orexo AB (publ.) announces that it has appealed the decision rendered by the United States District Court for the District of Delaware on November 15, 2016 regarding the validity of Orexo’s US Patent No. ... |
| - | Orexo appoints Joseph DeFeo as new CFO | Uppsala, Sweden – October 24, 2018 – Orexo AB announces today that the company appoints Joseph DeFeo as the company’s new Chief Financial Officer (CFO) from November 1, 2018. Joseph DeFeo will succeed Henrik Juuel who will join the Danish c... |
| - | Orexo issues a SEK 500 million bond loan on the Swedish bond market |
Uppsala, Sweden – April 30, 2014 –
Orexo AB (publ) has decided to issue a four-year senior unsecured bond loan of SEK 500 million with maturity on May 9, 2018. The bond loan will have a floating interest rate of Stibor 3m + 4.00% and a t... |
| - | Orexo commences patent infringement litigation against Actavis | Uppsala, Sweden – June 27, 2014 – Orexo AB today announced that it has filed a patent infringement action in United States District Court for the District of Delaware, against Actavis Elizabeth LLC and its parent company Actavis, Inc. (coll... |
| - | Top-line data from a Phase 3 clinical trial demonstrates that Zubsolv® is as effective as Suboxone® film in the treatment of opioid dependence | Uppsala, Sweden – June 25, 2014 – Orexo announces top-line data from a Phase 3 clinical trial demonstrating that Zubsolv® (buprenorphine/naloxone CIII sublingual tablet) is as effective as Suboxone® film in the treatment of opioid dependenc... |
| - | Interim Report January-March 2016 | Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015.
Orexo reports positive cash flow for the quarter
First quarter 2016
Teleconference
CEO Nikolaj Søre... |
| - | Interim report January-March 2015 | Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014.
First quarter shows continued sales growth and positive cash flow. Broadening of Zubsolv® dosage range... |
| - | ZUBSOLV® Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid | Uppsala, Sweden – August 4, 2015 – Orexo AB announced today changes to ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) managed care formularyPOSITION for patients suffering from opioid dependence.
Today the PBM, CVS Caremark publi... |
| - | Invitation – Orexo Digital Therapeutics business update October 1 | Uppsala, Sweden – September 25, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm CET.
During the event, Orexo will provide an update on ... |
| - | Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health | Uppsala, Sweden – December 2, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has appointed Dennis Urbaniak as Executive Vice P... |
| - | Orexo submits application to FDA for expanded label of ZUBSOLV® | Uppsala, Sweden – October 13, 2014 – Orexo AB (publ) announces today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for an expanded label of ZUBSOLV (buprenorphine/naloxone CIII sublingual tablet) to inc... |
| - | Orexo appoints Nomination Committee and publishes financial calendar 2014/2015 | Prior to the Annual General Meeting 2015, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information.
The Nomination Comm... |
| - | Orexo’s “Out the Monster” campaign wins a Gold Lions Health Award at the Cannes Lions Festival | Morristown, NJ – June 25, 2015 – Orexo’s “Out the Monster” campaign came out on top with a Gold Lions Health Award at the Cannes Lions Festival in France on June 19th. The Lions Health Awards recognize the most creative ideas in the healthc... |
| - | Mundipharma and Orexo announce EU regulatory submission for Zubsolv® | Cambridge, UK and Uppsala, Sweden– 4 October, 2016 Mundipharma and Orexo AB (publ.) have announced the submission of a regulatory submission of a Marketing Authorisation Application (MAA) for Zubsolv (buprenorphine and naloxone) sublingual ... |
| - | Orexo commences patent infringement litigation against Actavis concerning Abstral® in the US | Uppsala, Sweden – February 05, 2015 – Orexo AB, today announced that it has filed a patent infringement action in United States District Court for the District of New Jersey, against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis... |
| - | Orexo announces new US patent for ZUBSOLV® | Uppsala, Sweden – December 30, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo’s sublingual buprenorphine and naloxone tablet (CII)... |
| - | Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options | Morristown, New Jersey, September 9, 2020 – Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alc... |
| - | Favorable outcome from Zubsolv® patent infringement litigation against Actavis | Uppsala, Sweden, November 16, 2016 – Orexo AB (publ.) announces that the United States District Court for the District of Delaware ruled in Orexo’s favor in one of the patent infringement litigations against Actavis Elizabeth LLC (“Actavis”... |
| - | AstraZeneca acquires all rights to Orexo´s OX-CLI project | Uppsala, Sweden – March 17, 2016 – Orexo AB (publ) today announced that AstraZeneca has decided to acquire all rights to the leukotriene C4 synthase inhibitor program (OX-CLI project) for MUSD 5. AstraZeneca established a collaboration with... |
| - | Orexo Completes Bond Buyback Program | Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59. The program was i... |
| - | Zubsolv® gains preferred position on CVS Caremark 2018 formulary | Uppsala, Sweden – August 2, 2017 – Orexo AB announced today changes to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence. Zubsolv’s ... |
| - | Orexo has successfully completed its private placement of approx. SEK 346.5m | Uppsala, Sweden – August 29, 2014 – Orexo AB (publ) today announces that its private placement of 2,493,046 Orexo shares has been completed. The placement included all Orexo shares held in treasury by the company in addition to newly issued... |
| - | Orexo divests subsidiary Kibion | Uppsala, Sweden – April 30, 2015 – Orexo AB today announced the divestment of the subsidiary Kibion AB that markets the products Heliprobe® System, Diabact® UBT and IRIS™ for the diagnosis of the gastric ulcer bacterium Helicobacter pylori ... |
| - | Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US | Uppsala, Sweden – August 10, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces it has received a “paragraph IV” patent certification notice from Sun Pharmaceutical Industries Limited (“Sun”). The Notice Letter advises Orexo ... |
| - | Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder | UPPSALA, SWEDEN, AND NEW YORK, NY, USA, June 17th, 2020: Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Inno... |
| - | Report from Orexo AB’s annual general meeting, 15 April 2015 | Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 15 April 2015 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be six with no deputy bo... |
| - | Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv® | Uppsala, Sweden – June 30, 2016 – Orexo AB (publ.) today announced an agreement granting Mundipharma’s network of independent associated companies´ exclusive global (ex-US) rights to Zubsolv® (buprenorphine and naloxone) sublingual tablet (... |
| - | Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV[® ]in Europe | Uppsala, Sweden – December 7, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of ZUBSOLV® ((buprenorphine (as hydrochloride) and naloxone (... |
| - | Orexo signs asset purchase agreement with Gesynta Pharma AB for OX-MPI | Uppsala, Sweden – October 2, 2017 – Orexo AB (publ.) today announced that Orexo has signed an asset purchase agreement with Gesynta Pharma AB – a recently formed research company located in Stockholm, Sweden. Among the founders are highly r... |
| - | U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence | Uppsala, Sweden – August 11, 2015 – Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) for induction of buprenorphine maintenance therapy in... |
| - | Invitation to attend a teleconference on July 2, 1.30 pm CET – DTx US commercialization plan | Uppsala, Sweden – July 2, 2020 – Due to today´s announcement the US launch of deprexis® and vorvida® has been initiated and the decision to accelerate the launch of the company´s full digital offering, also incl. OXD01, analysts, investors ... |
| - | Orexo receives million 5£ milestone payment for Abstral® in Europe and Zubsolv® continues strong market share growth in the US | Uppsala, Sweden – December 17, 2014 – The annual sales of Abstral in Europe has passed million 60€ during 2014, which triggers a milestone payment of million 5£ (approx. million 60 SEK) to Orexo AB (”Orexo”) from the commercial partner in E... |
| - | Orexo publishes prospectus and applies for admission to trading of corporate bonds | Uppsala, Sweden – March 16 2021 – On 4 February 2021, Orexo AB (publ) (the “Company”) announced its successful issue of senior unsecured bonds in an amount of SEK 500 million, within a framework amount of SEK 1 billion (the “Bonds”) The Bon... |
